
December is recognized nationally as Impaired Driving Prevention Month, which spotlights the dangers of getting behind the wheel under the influence of drugs or alcohol. According to the Substance Abuse and Mental Health Services Administration, 12.6 million Americans drove drunk in 2025 — and an additional 10.3 million operated a vehicle after using marijuana (cannabis).
More than half of the drivers seriously injured in crashes on United States roads tested positive for either alcohol or drugs. One-quarter had detectable levels of
Delta-9-tetrahydrocannabinol (THC), the main psychoactive chemical in cannabis, edging out alcohol by two percentage points. Although residual THC can linger in the body for weeks and potentially inflate these numbers, driving while high remains dangerous.
Combining cannabis with alcohol increases the chance of a fatal traffic accident by up to 25 times compared to using either substance alone. While an overwhelming majority of Americans acknowledge that driving drunk is extremely dangerous, nearly one-third consider it safe to drive an hour after consuming a cannabis product. Some think cannabis improves their driving.
As more states expand access to medical and recreational cannabis, researchers remain divided on how legalization has influenced motor vehicle accident rates.
THC stimulates a complex nerve grid originating in the mid-brain, and triggers a massive surge of euphoria-inducing dopamine. Regular use lessens this effect, and more product is needed to achieve the same outcome. The dopamine burst also affects movement and cognition. Driving is impacted because THC can alter time and distance perception, cloud judgement, and reduce coordination. Cannabis-impaired drivers have slower reaction times — making it harder for them to suddenly brake for pedestrians. Collision risks increase because affected users are frequently inattentive and more likely to weave in and out of lanes.
THC effects vary widely, depending on the dose, frequency of use, and how it’s consumed. Inhaled cannabis enters the bloodstream directly through the lungs, causing euphoria that begins in as little as one minute and fades within four to six hours. In contrast, edibles may take up to two hours to have an effect. The liver must first metabolize oral THC into 11-hydroxy-THC — a potent compound whose impact can linger as long as 12 hours. Sublingual cannabis products, such as drops, lozenges, and tinctures, may affect the user within 15 minutes and last up to three hours.
Medical cannabis — often used to ease chemotherapy-induced nausea or HIV/AIDS-related weight loss — typically contains low amounts of THC, around 2.5 to 5 mg per serving. Cannabis products sold in dispensaries or unregulated markets are generally more potent and 5 to 10 mg of THC per serving. Vaping may deliver up to 50 mg per session — roughly 30 times stronger than the natural cannabis smoked in the 1970s.
These wide differences in THC dosage and metabolism make measuring cannabis impairment a major challenge. While a blood alcohol test accurately reflects how drunk a person is, THC levels in the blood do not reliably show whether someone is currently affected by cannabis. A November 2025 study published in Clinical Chemistry found that regular users who abstained for 48 hours still had significant THC levels, but were not euphoric or driving impaired.
THC’s fat-soluble nature leaves inactive trace amounts and chemical byproducts in the blood, urine, and saliva of users for more than 30 days, causing misleading positive test results. Cannabidiol (CBD) products advertised as “THC-free” commonly contain detectable amounts of the drug, too, and can skew testing outcomes.
Nationwide, it is illegal to operate a vehicle while impaired by THC, which includes prescribed or authorized medical cannabis. Each state sets and enforces its own cannabis-use driving laws, which fall into three broad categories.,
Zero-tolerance, mandated in 10 states, prohibits driving with any detectable trace of THC in blood, urine, or saliva. Seven states have a “per se” law, where a legal THC limit is based on a blood test similar to the one for alcohol. Called per se after the Latin phrase meaning “by itself,” any THC measured above the state’s mandated threshold is illegal by itself, regardless of whether driving is impaired or not.
The remaining 33 states, including New York, have a general “under the influence” standard, simply prohibiting driving when impaired. The New York law requires actual proof that the driver is drug-affected. Because THC concentration in blood, urine, and saliva does not reliably correlate with driving impairment, law enforcement officers must rely on subjective roadside assessments of observed behavior and field sobriety tests — developed to detect drunk drivers, not designed or scientifically validated to identify specific types of drug impairment.
Despite the disconnect between salivary testing and cannabis intoxication, New York police often use roadside voluntary SoToxa oral swabs (screening for THC and six other drugs, including fentanyl and cocaine) along with a statewide lab-based saliva testing program, both launched in 2024. A positive result only shows that cannabis was recently in the mouth; it cannot assess impairment or pinpoint precisely when the drug was consumed.
Those arrested for driving under the influence of cannabis may also undergo a Drug Recognition Expert evaluation — an interview and physical assessment that is performed at a police station to determine the cause of impairment.
New York penalties for a DWAI-Drug (Driving While Ability Impaired by Drugs) are $500 to $1,000 and up to one year in jail. The fine can be as much as $5,000 for a second offense, with up to four years in prison.
If you choose to consume cannabis, make a transportation plan beforehand to prevent serious motor vehicle accidents. Avoid driving or operating machinery for at least six to eight hours after using inhaled, sublingual, or prescription cannabis; and for at least eight to 12 hours after ingesting edibles.
Dr. Mary Jenkins, a contributor to the Herald and member of its board of directors, retired after nearly 40 years as a family practice physician in New York state.

